Baseline Immunological Profile in Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial

被引：0
|
作者：
Mao-Draayer, Yang [1 ]
Wu, Qi [1 ]
Wang, Qin [1 ]
Lundy, Steve K. [1 ]
Dowling, Catherine [1 ]
Segal, Benjamin Matthew M. [1 ]
Fox, David [1 ]
Wallstroem, Erik [2 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Novartis Pharma AG, Basel, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P011
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [31] Magnetization Transfer Imaging in Secondary Progressive Multiple Sclerosis Patients Treated with Siponimod: Results from the Phase 3 EXPAND Study
    Arnold, Douglas L.
    Cree, Bruce A. C.
    Bar-Or, Amit
    Giovannoni, Gavin
    Gold, Ralf
    Vermersch, Patrick
    Meier, Daniela Piani
    Arnould, Sophie
    Ritter, Shannon
    Karlsson, Goeril
    Kappos, Ludwig
    Fox, Robert
    NEUROLOGY, 2020, 94 (15)
  • [32] Baseline Characteristics in the Tolebrutinib Phase 3 Non-Relapsing Secondary Progressive Multiple Sclerosis (nrSPMS) HERCULES Clinical Trial
    Fox, Robert J.
    Bar-Or, Amit
    Traboulsee, Anthony
    Oreja-Guevara, Celia
    Giovannoni, Gavin
    Vermersch, Patrick
    Dukovic, Deborah
    Vargas, Wendy S.
    Syed, Sana
    Turner, Timothy
    Reich, Daniel
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 938 - 939
  • [33] Safety and efficacy of siponimod in patients with active secondary progressive multiple sclerosis identifying as Hispanic from the phase 3 EXPAND study
    Cohan, S.
    Hua, L. H.
    Bar-Or, A.
    Lublin, F. D.
    Meng, X.
    Cox, G. M.
    Coyle, P. K.
    Fox, R. J.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 590 - 591
  • [34] The lymphocyte subpopulation in patients with primary progressive multiple sclerosis and secondary progressive multiple sclerosis
    Belniak, Ewa
    Bojarska-Junak, Agnieszka
    Bartosik-Psujek, Halina
    Mitosek-Szewezyk, Krystyna
    Kulka, Malgorzata
    Stelmasiak, Zbigniew
    Rolinski, Jacek
    MULTIPLE SCLEROSIS, 2008, 14 : S116 - S116
  • [35] Efficacy and safety of siponimod in secondary progressive multiple sclerosis - Results of the placebo controlled, double-blind, Phase III EXPAND study.
    Kappos, L.
    Bar-Or, A.
    Cree, B.
    Fox, R.
    Giovannoni, G.
    Gold, R.
    Vermersch, P.
    Arnould, S.
    Sidorenko, T.
    Wolf, C.
    Wallstroem, E.
    Dahlke, F.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 828 - 829
  • [36] Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of two phase III trials
    Dzau, Winston
    Roos, Izanne
    Kalincik, Tomas
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2025,
  • [37] The cladribine trial in secondary progressive multiple sclerosis: A reanalysis
    Beutler, E
    Koziol, JA
    NEUROEPIDEMIOLOGY, 2000, 19 (02) : 109 - 112
  • [38] A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis
    Kita, M
    Goodkin, DE
    Bacchetti, P
    Stone, J
    Waubant, E
    Pelletier, D
    Nelson, SJ
    NEUROLOGY, 2000, 54 (07) : A22 - A23
  • [39] A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis
    Kita, M
    Cohen, JA
    Fox, RJ
    Evangelista, A
    Pelletier, D
    Stone, J
    Goodkin, DE
    Zamvil, SS
    NEUROLOGY, 2004, 62 (07) : A99 - A99
  • [40] A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis
    Kita, M
    Pelletier, D
    Goodkin, D
    Fox, R
    Cohen, J
    Bacchetti, P
    Stone, J
    Hietpas, J
    Zamvil, S
    NEUROLOGY, 2001, 56 (08) : A149 - A149
12345